NCT05651594

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: RECRUITING

Phase: PHASE2

Sponsor: Roswell Park Cancer Institute

Condition: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.